Replies to post #238729 on Elite Pharmaceuticals Inc (ELTP)

[NASDAQ2020]

No overdose deterrence drugs exist maybe in ten years.
we only have oral(chewing), IV, and snorting labeling at this time.
Elite will have the best labeling to date with their IR ADF opiod.
There will be a bidding war after approval.
Im locked and loaded

Early retirement coming for many longs, GL

Don't mix up oral deterrence with overdosing

[NASDAQ2020]

Correct

"ELTP 2 bead antagonist ADF tech will easily qualify for IV, snorting, and chewing ADF label for every opioid agonist with any time-release characteristic

Thanx for sharing the DD

[NASDAQ2020]

What about immediate-release such as SequestOx ???????????????????

"ELTP 2 bead antagonist ADF tech(which includes SequestOX) will easily qualify for IV, snorting, and oral (chewing) ADF label for every opioid agonist with any time-release characteristic.

Im goin all in !!!!!!!!!!!

[WeeZuhl]

What about immediate-release such as SequestOx ???????????????????

ELTP 2 bead antagonist ADF tech will easily qualify for IV, snorting, and chewing ADF label for every opioid agonist with any time-release characteristic. No known company is within 10 years of marketing an effective overdose ADF.

Yes, IB, even immediate-release SequestOx will qualify for IV, snorting, and chewing ADF Label.




Picking up from our conversation yesterday about how doctors will prescribe only what the insurance will pay for: one place where that does not apply is the emergency department. ER docs could care less if a patient who they do not see regularly will have to pay $100 for #20 SequestOx instead of $20 for #20 oxyIR. In fact, they would prefer it so next time that patient calls their primary care doctor about their back/knee/hip pain. A little negative reinforcement for Gomer (GET OUT OF MY E.R., see House of God). Not to mention the peace of mind that would come from knowing that patient is not about to crush & inject.

We've done similar math before, but let's run the exercise again for late-comers.


40,000 ER docs in the U.S. with at least as many NP/PA's working in the ED, probably a lot more. Approx 80,000 E.R. providers.

Now add in Urgent Care. 10,000 urgent care clinics in the U.S. Each clinic probably has an average four docs and as many NP/PA's, so we'll approximate another 80,000 urgent care providers.

Approximately 160,000 E.R. and urgent care providers in the U.S.. We convince just 10% to switch to SequestOx, and they write an average of one script per shift- about 20 scripts in a month of 20 pills each.


160,000 x 10% = 16,000

16,000 x 20 scripts x 20 pills x 12 months = 76,800,000 capsules per year.





Now set your price. Say $5/capsule (approx. 5x of generic oxy capsules).



76,800,000 capsules x $5/cap = $384,000,000 / year in revenue just from 10% of ER and urgent care providers writing 1 SequestOx #20 script per shift.


Now what happens if you get buy-in from 25% of the those providers? 50%? Now start to add in pain management, primary care, and orthopedics.